Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. in Journal of thrombosis and thrombolysis / J Thromb Thrombolysis. 2021 Oct;52(3):797-807. doi: 10.1007/s11239-021-02439-x. Epub 2021 Apr 13.
2021
AOU Novara
Tipo pubblicazione
Randomized Controlled Trial
Autori/Collaboratori (26)Vedi tutti...
Roolvink V
Isala Hospital, Zwolle, The Netherlands.
Lee SWL
Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong.
Van't Hof AWJ
Isala Hospital, Zwolle, The Netherlands.
et alii...
Abstract
BACKGROUND: Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing percutaneous coronary interventions with drug eluting stents (DES). The impact of gender on the optimal duration of dual antiplatelet therapy (DAPT) in ACS patients is still unexplored and was, therefore, the aim of the present sub-study. METHODS: REDUCE was a prospective, multicenter, randomized investigator-initiated study designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a noninferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleedings (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months. RESULTS: From June 2014 to May 2016 300 women and 1196 men were included in the study. Among them, 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, with the exception of a lower rate of TIMI flow?
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 33847862
DOI : 10.1007/s11239-021-02439-x
Keywords
Treatment Outcome; Thrombosis; Stroke; Stents; Sex Factors; Prospective Studies; Platelet Aggregation Inhibitors/therapeutic use; Percutaneous Coronary Intervention; Male; Humans; Hemorrhage/chemically induced; Follow-Up Studies; Female; Drug Therapy, Combination; Acute Coronary Syndrome/drug therapy; ACS; Bleeding; DAPT duration; Gender; Mortality; PCI; Thrombosis;